Opportunities of metabolic treatment in paroxysmal atrial fibrillation patients with obesity, arterial hypertension and/or ischemic heart disease

Abstract

This article provides the experience of examination and treatment of paroxysmal atrial fibrillation patients with concomitant obesity, arterial hypertension and/or ischemic heart disease, who were prescribed levocarnitine in addition to traditional therapy. The addition of levocarnitine in management of atrial fibrillation was found to be capable of reducing the atrial fibrillation burden after cardioversion and improve the functional state of the patients.

Keywords

atrial fibrillation / levocarnitine / recurrence / prevention

References

[1] Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa945

[2] Hindricks G., Potpara T., Dagres N., et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC // Europ Heart J. 2021. Vol. 42, N. 5. P. 373–498. doi: 10.1093/eurheartj/ehaa945

[3] Trohman RG, Huang HD, Sharma PS. Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1. Front Cardiovasc Med. 2023;10:1060030. doi: 10.3389/fcvm.2023.1060030

[4] Trohman R.G., Huang H.D., Sharma P.S. Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1 // Front Cardiovasc Med. 2023. Vol. 10. P. 1060030. doi: 10.3389/fcvm.2023.1060030

[5] Vizzardi E, Curnis A, Latini MG, et al. Risk factors for atrial fibrillation recurrence: a literature review. J Cardiovasc Med (Hagerstown). 2014;15(3):235–253. doi: 10.2459/jcm.0b013e328358554b

[6] Vizzardi E., Curnis A., Latini M.G., et al. Risk factors for atrial fibrillation recurrence: a literature review // J Cardiovasc Med (Hagerstown). 2014. Vol. 15, N. 3. P. 235–253. doi: 10.2459/jcm.0b013e328358554b

[7] DiNicolantonio JJ, Lavie CJ, Fares H, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88(6):544–551. doi: 10.1016/j.mayocp.2013.02.007

[8] DiNicolantonio J.J., Lavie C.J., Fares H., et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis // Mayo Clin Proc. 2013. Vol. 88, N. 6. P. 544–551. doi: 10.1016/j.mayocp.2013.02.007

[9] Zhao G, Zhang H, Wang Y, et al. Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure. Hellenic J Cardiol. 2020;61(2):99–102. doi: 10.1016/j.hjc.2018.08.006

[10] Zhao G., Zhang H., Wang Y., et al. Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure // Hellenic J Cardiol. 2020. Vol. 61, N. 2. P. 99–102. doi: 10.1016/j.hjc.2018.08.006

[11] Kinugasa Y, Sota T, Ishiga N, et al. L-carnitine supplementation in heart failure patients with preserved ejection fraction; a pilot study. Geriatr Gerontol Int. 2020;20(12):1244–1245. doi: 10.1111/ggi.14060

[12] Kinugasa Y., Sota T., Ishiga N., et al. L-carnitine supplementation in heart failure patients with preserved ejection fraction; a pilot study // Geriatr Gerontol Int. 2020. Vol. 20, N. 12. P. 1244–1245. doi: 10.1111/ggi.14060

[13] Dastan F, Talasaz AH, Mojtahedzadeh M, et al. Randomized trial of carnitine for the prevention of perioperative atrial fibrillation. Semin Thorac Cardiovasc Surg. 2018;30:7–13. doi: 10.1053/j.semtcvs.2017.08.006

[14] Dastan F., Talasaz A.H., Mojtahedzadeh M., et al. Randomized trial of carnitine for the prevention of perioperative atrial fibrillation // Semin Thorac Cardiovasc Surg. 2018. Vol. 30. P. 7–13. doi: 10.1053/j.semtcvs.2017.08.006

[15] Shingu Y, Katoh N, Ooka T, et al. L-carnitine supplementation for the prevention of postoperative atrial fibrillation in aortic valve surgery. Gen Thorac Cardiovasc Surg. 2021;69(11):1460–1466. doi: 10.1007/s11748-021-01616-2

[16] Shingu Y., Katoh N., Ooka T., et al. L-carnitine supplementation for the prevention of postoperative atrial fibrillation in aortic valve surgery // Gen Thorac Cardiovasc Surg. 2021. Vol. 69, N. 11. P. 1460–1466. doi: 10.1007/s11748-021-01616-2

[17] Astashkin EI, Glezer MG. Cardiac lipotoxic effects of obesity. Arterial Hypertension. 2009;15(3):335–341. (In Russ.) doi: 10.18705/1607-419X-2009-15-3-335-341

[18] Асташкин Е.И., Глезер М.Г. Липотоксические эффекты в сердце, наблюдаемые при ожирении // Артериальная гипертензия. 2009. Т. 15, № 3. С. 335–341. doi: 10.18705/1607-419X-2009-15-3-335-341

[19] Zhang Y, Fu Y, Jiang T, et al. Enhancing fatty acids oxidation via L-carnitine attenuates obesity-related atrial fibrillation and structural remodeling by activating AMPK signaling and alleviating cardiac lipotoxicity. Front Pharmacol. 2021;12:771940. doi: 10.3389/fphar.2021.771940

[20] Zhang Y., Fu Y., Jiang T., et al. Enhancing fatty acids oxidation via L-carnitine attenuates obesity-related atrial fibrillation and structural remodeling by activating AMPK signaling and alleviating cardiac lipotoxicity // Front Pharmacol. 2021. Vol. 12. P. 771940. doi: 10.3389/fphar.2021.771940

[21] Muszyński P, Bonda TA. Mitochondrial dysfunction in atrial fibrillation-mechanisms and pharmacological interventions. J Clin Med. 2021;10(11):2385. doi: 10.3390/jcm10112385

[22] Muszyński P., Bonda T.A. Mitochondrial dysfunction in atrial fibrillation-mechanisms and pharmacological interventions // J Clin Med. 2021. Vol. 10, N. 11. P. 2385. doi: 10.3390/jcm10112385

[23] Gasparova I, Kubatka P, Opatrilova R, et al. Perspectives and challenges of antioxidant therapy for atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(1):1–14. doi: 10.1007/s00210-016-1320-9

[24] Gasparova I., Kubatka P., Opatrilova R., et al. Perspectives and challenges of antioxidant therapy for atrial fibrillation // Naunyn Schmiedebergs Arch Pharmacol. 2017. Vol. 390, N. 1. P. 1–14. doi: 10.1007/s00210-016-1320-9

[25] Sciatti E, Lombardi C, Ravera A, et al.. Nutritional deficiency in patients with heart failure. Nutrients. 2016;8(7):442. doi: 10.3390/nu8070442

[26] Sciatti E., Lombardi C., Ravera A., et al. Nutritional deficiency in patients with heart failure // Nutrients. 2016. Vol. 8, N. 7. H. 442. doi: 10.3390/nu8070442

[27] Song X, Qu H, Yang Z, et al. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials. Biomed Res Int. 2017;2017:6274854. doi: 10.1155/2017/6274854

[28] Song X., Qu H., Yang Z., et al. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials // Biomed Res Int. 2017. Vol. 2017. P. 6274854. doi: 10.1155/2017/6274854

[29] Trukhan DI. Role and location of L-carnitine in cytoprotection and correction of metabolic processes in patients with metabolic syndrome. Medical Council. 2017;(12):182–187. EDN: ZQTJYB doi: 10.21518/2079-701X-2017-12-182-187

[30] Трухан Д.И. Роль и место L-карнитина в цитопротекции и коррекции метаболических процессов у пациентов с метаболическим синдромом // Мед. совет. 2017. Т. 12. С. 182–7. EDN: ZQTJYB doi: 10.21518/2079-701X-2017-12-182-187

RIGHTS & PERMISSIONS

Eco-Vector